Research Unit, Dep. Q of Affective Disorders, Aarhus University Hospital, Risskov
Aarhus, Risskov, 8240, Denmark
NCT Number: NCT00957294
The metabolic syndrome (MetS) is highly prevalent in patients with schizophrenia and is a major risk factor of type-2 diabetes, cardiovascular disease and early death. Genetic factors, antipsychotic medication, sleeping disturbances and unhealthy lifestyle are possible causes of developing metabolic syndrome. Several studies have investigated the metabolic side-effects of antipsychotic medication. However it is still unanswered how unhealthy lifestyle, comprising physical inactivity, smoking, unhealthy dieting, and sleeping disturbances adds to the metabolic risk of patients with schizophrenia. The aim of this study is to investigate the prevalence and development of MetS in first-episode patients with schizophrenia and 1 year after onset of treatment. The study's main hypothesis is that physical inactivity, regardless of medication, is an independent risk factor for metabolic syndrome in patients with schizophrenia. In comparison inpatients with major depression and healthy controls, both matched on gender, age and level of education will be included in the study. It is anticipated that the study's results will provide new knowledge about the risk of developing metabolic syndrome in first-episode schizophrenia and how different risk factors contribute to this.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Observational
Aarhus, Risskov, 8240, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 year
Aarhus University Hospital
Other
The Metabolic Syndrome in Patients With First-episode Schizophrenia - Prognosis and Prediction.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00448630
Glucose Metabolism Disorders, Hyperinsulinism
Kurttepe, Adana, Turkey (Türkiye)
View Trial DetailsNCT02983188
Glucose Metabolism Disorders, Hyperinsulinism
Tuenmen, Hong Kong
View Trial DetailsNCT00338949
Glucose Metabolism Disorders, Hyperinsulinism
San Diego, California, United States
View Trial DetailsNCT01794429
Body Weight, Drug-induced Obesity
Glostrup Municipality, Denmark
View Trial Details